# Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA

> **NCT02629523** · PHASE2 · COMPLETED · sponsor: **Chonnam National University Hospital** · enrollment: 21 (actual)

## Conditions studied

- Lung Neoplasms
- EGFR Gene Mutation

## Interventions

- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT02629523
- **Lead sponsor:** Chonnam National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-01
- **Primary completion:** 2018-12-31
- **Final completion:** 2020-05-11
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02629523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02629523, "Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02629523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*